• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Sage Therapeutics

Quote




















anonymous said:
Glad you have other options. Sage isn't the end all be all. I have a friend that had a really good chance of getting hired, but decided to not limit themselves and settle for just Sage. They accepted an offer from another company making way more money than they would have at Sage and a position that matched their experience level. Although I thought we would be in training together, I'm very inspired by them not settling for less than what they deserve.
Keep your options open everyone. Lots of other companies are hiring and launching drugs with a great pipeline.
Click to expand...
 












anonymous said:
I have been monitoring Sage ever since a Mgr found me on LinkedIn. Currently, I am in the oncology infusion arena. The mgr gave me a call and like everyone should do, I listened to him.

This manager lost me very quickly. He admitted to having no infusion experience. In addition, this manager told me this therapy would be an “automatic gamechanger” in which there is no such thing.

As the conversation proceeded, he finally answered my question regarding salary range. The salary range is extremely sub-par if Sage is seeking reps experienced in infusion.

After politely saying “no thanks”, the manager began to ask me a slew of questions regarding the infusion process. This conversation quickly went from being unprofessional to down right silly and pitiful.

I’ll stand by what I told that manager approximately 2 months ago...you better get people that know the market/competition. You’ve got tons of oral treatments to beat in a highly genericized market.

The reason for my post is after reading multiple other posts about the company keeping business cases and brag books (f.y.i. It’s a HR violation to ask for and keep brag books—DO NOT leave them), I honestly feel like this company is blinded and has no direction or idea as to where it is going.

Bottom line...many of these posts match up with that “clueless” phone call I received a couple of months ago. Personally, I think Sage needs to hit the brakes and regroup. Delay your launch and get things right. You only have one chance to make a first impression.
Click to expand...
 




anonymous said:
I have been monitoring Sage ever since a Mgr found me on LinkedIn. Currently, I am in the oncology infusion arena. The mgr gave me a call and like everyone should do, I listened to him.

This manager lost me very quickly. He admitted to having no infusion experience. In addition, this manager told me this therapy would be an “automatic gamechanger” in which there is no such thing.

As the conversation proceeded, he finally answered my question regarding salary range. The salary range is extremely sub-par if Sage is seeking reps experienced in infusion.

After politely saying “no thanks”, the manager began to ask me a slew of questions regarding the infusion process. This conversation quickly went from being unprofessional to down right silly and pitiful.

I’ll stand by what I told that manager approximately 2 months ago...you better get people that know the market/competition. You’ve got tons of oral treatments to beat in a highly genericized market.

The reason for my post is after reading multiple other posts about the company keeping business cases and brag books (f.y.i. It’s a HR violation to ask for and keep brag books—DO NOT leave them), I honestly feel like this company is blinded and has no direction or idea as to where it is going.

Bottom line...many of these posts match up with that “clueless” phone call I received a couple of months ago. Personally, I think Sage needs to hit the brakes and regroup. Delay your launch and get things right. You only have one chance to make a first impression.
Click to expand...
what was the salary range?
 








anonymous said:
what did you think of the female Boston manager?
Click to expand...
I’ve not seen one female up in this joint except for the Patient Advocacy Team.....which strikes me super odd since this is a condition that afflicts PP women! I was beat out by a man, the Mgr is a Man. The KAM is a man, and the Area Director (mgrs’ mgr) is a Man. Good luck with that!
 








anonymous said:
I’ve not seen one female up in this joint except for the Patient Advocacy Team.....which strikes me super odd since this is a condition that afflicts PP women! I was beat out by a man, the Mgr is a Man. The KAM is a man, and the Area Director (mgrs’ mgr) is a Man. Good luck with that!
Click to expand...


Agreed and it will certainly be noticed in the field by customers.
 








anonymous said:
Why is your stock plummeting?
Click to expand...
Here you go little buddy. I know its hard trying to follow the market directly from cafe pharma...


Live TV
The Nasdaq is getting crushed. Here's why
By Danielle Wiener-Bronner, CNN Business
Updated 5:11 PM EDT, Mon October 08, 2018
New York (CNN Business)The Nasdaq is taking a hit as investors pull away from risky tech stocks.

During trading hours Monday, the tech-heavy index fell by as much as 1.8%. The Dow and S&P 500 fell as low as 0.8% percent each.

The Nasdaq closed down 0.7%, while the Dow closed slightly up. The S&P closed about flat.
Each of the FAANG stocks — Facebook (FB), Amazon (AMZN), Apple (AAPL), Netflix (NFLX) and Google -(GOOG) — declined.

Rising bond yields and interest rates are prompting investors to back away from tech, said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.

"Whenever you see rates rise in a rapid fashion, you typically see tech take a hit," he said. "As people start to get more concerned about the stock market in general, they pull back from more risky areas of the market."

Zaccarelli explained that investors see tech stocks as a long-run asset. When borrowing costs go up, investors see their payoff move further away, so they turn to more reliable bets like utilities and consumer staples.

Bond yields spiked following the jobs report on Friday. The benchmark 10-Year Treasury hit 3.24% -- its highest level in more than seven years.

The 10-year yield influences borrowing costs, including mortgage, car loan and credit card rates.
"You're now starting to see people price that in even to a greater extent today," Zaccarelli said of changes in the bond market.

Sam Stovall of CFRA Research said that "investors are trying to lock in whatever profits they have."

The Nasdaq is also vulnerable to the Fed and yields because it includes financial stocks, which could be impacted by higher interest rates, he said. That's because higher interest rates tend to slow growth, he said. When that happens, people and companies are less likely to borrow from banks.

That doesn't mean the Nasdaq will continue to fall.
 




















Top Bottom
Back
Quote